Baseline Findings of PreventE4: A Double-Blind Placebo Controlled Clinical Trial Testing High Dose DHA in APOE4 Carriers before the Onset of Dementia

• DOI: 10.14283/jpad.2023.77
• Publication Date: 2023-06-07T08:41:27Z
• Authors: Hussein Yassine; I.C. Arellanes; A. Mazmanian; L. De La Cruz; J. Martinez; L. Contreras; N. Kono; B.S. Liu; D. Badie; M.A. Bantugan; A. Grindon; T. Urich; L. D'Orazio; B.A. Emmanuel; H.C. Chui; W.J. Mack; M.G. Harrington; M.N. Braskie; L.S. Schneider
• Keywords: Aged, 80 and over; Docosahexaenoic Acids; Alzheimer Disease; Apolipoprotein E4; Fatty Acids, Omega-3; Humans; Brain; Middle Aged; 3. Good health; Aged

Lower blood levels of the omega-3 polyunsaturated fatty acid docosahexaenoic (DHA) are correlated with worse cognitive functions, particularly among APOE ε4 carriers. Whether DHA supplementation in carriers limited consumption and dementia risk factors can delay or slow down disease progression when started before onset clinical is not known. PreventE4 a double-blind, single site, randomized, placebo-controlled trial cognitively unimpaired individuals (n=368). Its objectives to determine (1) whether carrying allele associated lower delivery brain; (2) high dose affects brain imaging biomarkers AD function. 365 between 55 80 (mean age 66) were randomized 2 grams per day identically appearing placebo for period years. Half participants asked complete lumbar punctures at baseline 6-month visits obtain cerebrospinal fluid (CSF). The primary outcome measure change CSF arachidonic ratio after 6 months intervention (n=181). Secondary outcomes include functional structural connectivity using resting state MRI 24 (n=365). Exploratory Repeatable Battery Assessment Neuropsychological Status Findings from will clarify implications prevention strategies. Trial was registered as NCT03613844.